Metallothionein and cardiomyopathy

Metallothioneins in Biochemistry and Pathology

Volumn , Issue , 2008, Pages 227-270

  Cai, Lu ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Adriamycin; Cardiomyopathy; Diabetes; Diabetic cardiomyopathy; Doxorubicin; Ethanol; Ischemia and reperfusion

Indexed keywords

EID: 84969695771     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812778949_0012     Document Type: Chapter

References (134)

1. Abel J, de Ruiter N. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein. Toxicol Lett 1989; 47: 191-196.
2. Al-Maroof RA, Al-Sharbatti SS. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J 2006; 27: 344-350.
3. Ali MM, Frei E, Straub J, et al. Induction of metallothionein by zinc protects from daunoru-bicin toxicity in rats. Toxicology 2002; 179: 85-93.
4. Atahan E, Ergun Y, Belge Kurutas E, et al. Ischemia-reperfusion injury in rat skeletal muscle is attenuated by zinc aspartate. JSurg Res 2007; 137: 109-116.
5. 2+]; and metalloth-ionein level of rat heart via restoration of cell redox cycle. Am J Physiol Heart Circ Physiol 2006; 290: H1071-H1080.
6. Bauman JW, Liu J, Liu YP, Klaassen CD. Increase in metallothionein produced by chemicals that induce oxidative stress. Toxicol Appl Pharmacol 1991; 110: 347-354.
7. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 2006; 41: 851-861.
8. Cai L. Diabetic cardiomyopathy and its prevention by metallothionein: Experimental evidence, possible mechanisms and clinical implications. Curr Med Chem 2007; 14: 2193-2203.
9. Cai L, Cherian MG. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper-or cadmium-metallothioneins. Toxicol Lett 2003; 136: 193-198.
10. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: A brief review. Cardiovasc Toxicol 2001; 1: 181-193.
11. Cai L, Klein J, Kang YJ. Metallothionein prevents diabetic cardiomyopathy. Toxicol Sci 2001; 60(Suppl 1):13.
12. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem 2000; 275: 38957-38960.
13. Cai L, Koropatnick J, Cherian MG. Metallothionein protects DNA from copper-induced but not iron-induced cleavage in vitro. Chem Biol Interact 1995; 96: 143-155.
14. Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 2002; 51: 1938-1948.
15. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: Its induction and protective role. Toxicology 1999; 132: 85-98.
16. Cai L, Tsiapalis G, Cherian MG. Protective role of zinc-metallothionein on DNA damage in vitro by ferric nitrilotriacetate (Fe-NTA) and ferric salts. Chem Biol Interact 1998; 115: 141-151.
17. Cai L, Wang J, Li Y, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005; 54: 1829-1837.
18. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688-1697.
19. Cameron NE, Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 1995; 96: 1159-1163.
20. Canatan H, Bakan I, Akbulut M, et al. Relationship among levels of leptin and zinc, copper, and zinc/copper ratio in plasma of patients with essential hypertension and healthy normotensive subjects. Biol Trace Elem Res 2004; 100: 117-123.
21. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. CircRes 2003; 92: 785-792.
22. Canesi L, Betti M, Ciacci C, Gallo G. Insulin-like effect of zinc in Mytilus digestive gland cells: Modulation of tyrosine kinase-mediated cell signaling. Gen Comp Endocrinol 2001; 122: 60-66.
23. Ceylan-Isik AF, LaCour KH, Ren J. Gender disparity of streptozotocin-induced intrinsic contractile dysfunction in murine ventricular myocytes: Role of chronic activation of Akt. Clin Exp Pharmacol Physiol 2006a; 33:102-108.
24. Ceylan-Isik AF, LaCour KH, Ren J. Sex difference in cardiomyocyte function in normal and metallothionein transgenic mice: The effect of diabetes mellitus. J Appl Physiol 2006b; 100:1638-1646.
25. Ceylan-Isik AF, Wu S, Li Q, et al. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. JAppl Physiol 2006c; 100:150-156.
26. Chen HS, Shan YX, Yang TL, et al. Insulin deficiency downregulated heat shock protein 60 and IGF-1 receptor signaling in diabetic myocardium. Diabetes 2005; 54: 175-181.
27. Chen K, Zhang J, Ye C. [Metallothionein involvement in the delayed protection after ischemic or anoxic preconditioning in myocardium or cultured cardiomyocytes]. Zhonghua Yi Xue Za Zhi 1997; 77: 106-110.
28. Chen MF, Chang CL, Liou SY. Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif 1998a; 16:290-300.
29. Chen Y, Saari JT, Kang YJ. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic Biol Med 1994; 17: 529-536.
30. Chen Z, Chua CC, Ho YS, et al. Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol Heart Circ Physiol 2001; 280: H2313-H2320.
31. Chen Z, Siu B, Ho YS, et al. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. J Mol Cell Cardiol 1998b; 30: 2281-2289.
32. Cooper GJ, Chan YK, Dissanayake AM, et al. Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: Quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes, 2005; 54:1468-1476.
33. Cooper GJ, Phillips AR, Choong SY, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 2004; 53: 2501-2508.
34. Davies MJ. The cardiomyopathies: An overview. Heart 2000; 83: 469-474.
35. Dong F, Li Q, Sreejayan N, et al. Metallothionein prevents high fat diet-induced cardiac contractile dysfunction: Role of peroxisome proliferator-activated receptor {gamma} coactivator-1{alpha} and mitochondrial biogenesis. Diabetes 2007; 56: 2201-2212.
36. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin. J Clin Invest 1980; 65: 128-135.
37. Duan J, Zhang HY, Adkins SD, et al. Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: Role of Akt and RhoA. Am J Physiol Endocrinol Metab 2003; 284: E366-E376.
38. Eaton JW, Qian M. Interactions of copper with glycated proteins: Possible involvement in the etiology of diabetic neuropathy. Mol Cell Biochem 2002a; 234-235:135-142.
39. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002b; 32:833-840.
40. Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989; 58: 1067-1073.
41. Fang CX, Dong F, Ren BH, et al. Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: Role of Akt phosphorylation, PTB1B, PPARgammaand c-Jun. Diabetologia 2005; 48: 2412-2421.
42. Feng W, Benz FW, Cai J, et al. Metallothionein disulfides are present in metallothionein-overexpressing transgenic mouse heart and increase under conditions of oxidative stress. J Biol Chem 2006; 281: 681-687.
43. Fernandez-Sola J, Fatjo F, Sacanella E, et al. Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol 2006; 37: 1100-1110.
44. Formigari A, Irato P, Santon A. Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: Biochemical and cytochemical aspects. Comp Biochem Physiol C Toxicol Pharmacol 2007; 146: 443-459.
45. French JP, Quindry JC, Falk DJ, et al. Ischemia-reperfusion-induced calpain activation and SERCA2a degradation are attenuated by exercise training and calpain inhibition. Am J Physiol Heart Circ Physiol 2006; 290: H128-H136.
46. Garg S, Narula J, Chandrashekhar Y. Apoptosis and heart failure: Clinical relevance and therapeutic target. J Mol Cell Cardiol 2005; 38: 73-79.
47. Gregorio GV, Dans LF, Cordero CP, Panelo CA. Zinc supplementation reduced cost and duration of acute diarrhea in children. J Clin Epidemiol 2007; 60: 560-566.
48. Gross ER, Hsu AK, Gross GJ. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta. Diabetes 2007; 56: 127-136.
49. Hall AG, Kelleher SL, Lonnerdal B, Philipps AF. A graded model of dietary zinc deficiency: Effects on growth, insulin-like growth factor-I, and the glucose/insulin axis in weanling rats. J Pediatr Gastroenterol Nutr 2005; 41: 72-80.
50. Hamada Y, Nakashima E, Naruse K, et al. A copper chelating agent suppresses carbonyl stress in diabetic rat lenses. J Diabetes Complications 2005; 19: 328-334.
51. Hollander JM, Martin JL, Belke DD, et al. Overexpression of wild-type heat shock protein 27 and a nonphosphorylatable heat shock protein 27 mutant protects against ischemia/reperfusion injury in a transgenic mouse model. Circulation 2004; 110: 3544-3552.
52. Huisamen B. Protein kinase B in the diabetic heart. Mol Cell Biochem 2003; 249: 31-38.
53. Ihara Y, Kageyama K, Kondo T. Overexpression of calreticulin sensitizes SERCA2a to oxidative stress. Biochem Biophys Res Commun 2005; 329: 1343-1349.
54. Islam KN, Takahashi M, Higashiyama S, et al. Fragmentation of ceruloplasmin following non-enzymatic glycation reaction. J Biochem 1995; 118: 1054-1060.
55. Kaneko M, Bucciarelli L, Hwang YC, et al. Aldose reductase and AGE-RAGE pathways: Key players in myocardial ischemic injury. Ann NY Acad Sci 2005; 1043: 702-709.
56. Kang YJ. The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 1999; 222: 263-273.
57. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 1996; 271: 12610-12616.
58. Kang YJ, Chen Y, Yu A, et al. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 1997; 100: 1501-1506.
59. Kang YJ, Li G, Saari JT. Metallothionein inhibits ischemia-reperfusion injury in mouse heart. Am J Physiol 1999; 276: H993-H997.
60. Kang YJ, Li Y, Sun X, Sun X. Antiapoptotic effect and inhibition of ischemia/reperfusion-induced myocardial injury in metallothionein-overexpressing transgenic mice. Am J Pathol 2003; 163: 1579-1586.
61. Kang YJ, Sun X, Chen Y, Zhou Z. Inhibition of doxorubicin chronic toxicity in catalaseoverexpressing transgenic mouse hearts. Chem Res Toxicol 2002; 15: 1-6.
62. Kang YJ, Zhou ZX, Wang GW, et al. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 2000a; 275:13690-13698.
63. Kang YJ, Zhou ZX, Wu H, et al. Metallothionein inhibits myocardial apoptosis in copper-deficient mice: Role of atrial natriuretic peptide. Lab Invest 2000b; 80:745-757.
64. Karaca Z, Tanriverdi F, Kurtoglu S, et al. Pubertal arrest due to Zn deficiency: The effect of zinc supplementation. Hormones (Athens) 2007; 6: 71-74.
65. Karagulova G, Yue Y, Moreyra A, et al. Protective role of intracellular zinc in myocardial ischemia/reperfusion is associated with preservation of protein kinase C isoforms. J Pharmacol Exp Ther 2007; 321: 517-525.
66. Kosar F, Nisanoglu V, Aksoy Y, et al. Effects of coronary revascularization and concomitant aneurysmectomy on QT interval duration and dispersion. J Electrocardiol 2006; 39: 194-198.
67. Kralik PM, Ye G, Metreveli NS, et al. Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovasc Toxicol 2005; 5: 285-292.
68. Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: A feature of diabetic cardiomyopathy? Horm Metab Res 2007; 39: 672-676.
69. Lang CH, Frost RA, Summer AD, Vary TC. Molecular mechanisms responsible for alcohol-induced myopathy in skeletal muscle and heart. Int J Biochem Cell Biol 2005; 37: 2180-2195.
70. Li G, Chen Y, Saari JT, Kang YJ. Catalase-overexpressing transgenic mouse heart is resistant to ischemia-reperfusion injury. Am J Physiol 1997; 273: H1090-H1095.
71. Li Q, Ren J. Cardiac overexpression of metallothionein attenuates chronic alcohol intake-induced cardiomyocyte contractile dysfunction. Cardiovasc Toxicol 2006a; 6:173-182.
72. Li Q, Ren J. Cardiac overexpression of metallothionein rescues chronic alcohol intake-induced cardiomyocyte dysfunction: Role of Akt, mammalian target of rapamycin and ribosomal p70s6 kinase. Alcohol Alcohol 2006b; 41:585-592.
73. Liang Q, Carlson EC, Donthi RV, et al. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-181.
74. Lin LC, Que J, Lin KL, et al. Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: A double-blinded randomized study. Int J Radiat Oncol Biol Phys 2008; 70: 368-373.
75. Liu L, Zhang X, Qian B, et al. Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 2007; 9: 762-769.
76. 2+-ATPase in human heart failure. Circulation 2005; 111: 988-995.
77. Malaiyandi LM, Dineley KE, Reynolds IJ. Divergent consequences arise from metalloth-ionein overexpression in astrocytes: Zinc buffering and oxidant-induced zinc release. Glia 2004; 45: 346-353.
78. Maret W, Kre¸z˙el A. Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Mol Med 2007; 13: 371-375.
79. Matsushima S, Kinugawa S, Ide T, et al. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 2006; 291: H2237-H2245.
80. Moriarty-Craige SE, Ha KN, Sternberg P Jr, et al. Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration. Am J Ophthalmol 2007; 143: 206-211.
81. Naganuma A, Satoh M, Imura N. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn J Cancer Res 1988; 79: 406-411.
82. Nath R, Kumar D, Li T, Singal PK. Metallothioneins, oxidative stress and the cardiovascular system. Toxicology 2000; 155: 17-26.
83. Onody A, Zvara A, Hackler L Jr, et al. Effect of classic preconditioning on the gene expression pattern of rat hearts: A DNA microarray study. FEES Lett 2003; 536: 35-40.
84. Ookawara T, Kawamura N, Kitagawa Y, Taniguchi N. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J Eiol Chem 1992; 267: 18505-18510.
85. Oshima Y, Fujio Y, Nakanishi T, et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 2005; 65: 428-435.
86. Pacher P, Liaudet L, Bai P, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003; 107: 896-904.
87. Privratsky JR, Wold LE, Sowers JR, et al. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: Role of the AT1 receptor and NADPH oxidase. Hypertension 2003; 42: 206-212.
88. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": Implications for the pathogenesis of certain diabetic complications. Eiochem Eiophys Res Commun 1998; 250: 385-389.
89. 2 with sulfhydryl groups in HL-60 cells: Zinc-metallothionein and other sites. Arch Eiochem Eiophys 1996; 334: 241-250.
90. Reiterer G, MacDonald R, Browning JD, et al. Zinc deficiency increases plasma lipids and atherosclerotic markers in LDL-receptor-deficient mice. J Nutr 2005; 135: 2114-2118.
91. Roussel AM, Kerkeni A, Zouari N, et al. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr 2003; 22: 316-321.
92. Saito K, Ishizaka N, Aizawa T, et al. Iron chelation and a free radical scavenger suppress angiotensin II-induced upregulation of TGF-beta1 in the heart. Am J Physiol Heart Circ Physiol 2005; 288: H1836-H1843.
93. Satoh M, Naganuma A, Imura N. Involvement of cardiac metallothionein in prevention of adriamycin induced lipid peroxidation in the heart. Toxicology 1988; 53: 231-237.
94. Satoh M, Naganuma A, Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci 2000; 67: 627-634.
95. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006; 55: 798-805.
96. Shioji K, Kishimoto C, Nakamura H, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002; 106: 1403-1409.
97. Shuai Y, Guo J, Peng SQ, Zhang LS. [Metallothionein inhibited DOX-induced cardiac apoptosis in mice]. Sichuan Da Xue Xue Eao Yi Xue Ean 2007a; 38:620-623.
98. Shuai Y, Guo JB, Peng SQ, et al. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol Lett 2007b; 170:66-74.
99. Shukla N, Maher J, Masters J, et al. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis 2006; 187: 238-250.
100. Simon SF, Taylor CG. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp Biol Med (Maywood) 2001; 226: 43-51.
101. Soinio M, Marniemi J, Laakso M, et al. Serum zinc level and coronary heart disease events in patients with type 2 diabetes. Diabetes Care 2007; 30: 523-528.
102. Song Y, Wang J, Li XK, Cai L. Zinc and the diabetic heart. Biometals 2005a; 18:325-332.
103. Song Y, Wang J, Li Y, et al. Cardiac metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol 2005b; 167:17-26.
104. Sun X, Kang YJ. Prior increase in metallothionein levels is required to prevent doxorubicin cardiotoxicity. Exp Biol Med (Maywood) 2002; 227: 652-657.
105. Sun X, Zhou Z, Kang YJ. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res 2001; 61: 3382-3387.
106. Takahashi M, Saito H, Higashimoto M, Hibi T. Possible inhibitory effect of oral zinc supplementation on hepatic fibrosis through downregulation of TIMP-1: A pilot study. Hepatol Res 2007; 37: 405-409.
107. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007; 49: 330-352.
108. Tang X, Shay NF. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and Akt in 3T3-L1 fibroblasts and adipocytes. J Nutr 2001; 131: 1414-1420.
109. Thiene G, Angelini A, Basso C, et al. The new definition and classification of cardiomyopathies. Adv Clin Path 2000; 4: 53-57.
110. Thornalley PJ, Vašák M. Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim Biophys Acta 1985; 827: 36-44.
111. Trost SU, Belke DD, Bluhm WF, et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002; 51: 1166-1171.
112. Turdi S, Li Q, Lopez FL, Ren J. Catalase alleviates cardiomyocyte dysfunction in diabetes: Role of Akt, Forkhead transcriptional factor and silent information regulator 2. Life Sci 2007; 81: 895-905.
113. Turko IV, Marcondes S, Murad F. Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol Heart Circ Physiol 2001; 281: H2289-H2294.
114. 67Cu metabolism and oxidant defense in the rat. J Nutr Biochem 2005; 16: 312-320.
115. Van Campenhout A, Van Campenhout C, Lagrou AR, et al. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic Biol Med 2006; 40: 1749-1755.
116. Vasquez-Vivar J, Martasek P, Hogg N, et al. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 1997; 36: 11293-11297.
117. Wang GW, Klein JB, Kang YJ. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J Pharmacol Exp Ther 2001a; 298:461-468.
118. Wang GW, Zhou Z, Klein JB, Kang YJ. Inhibition of hypoxia/reoxygenation-induced apoptosis in metallothionein-overexpressing cardiomyocytes. Am J Physiol Heart Circ Physiol 2001b; 280:H2292-H2299.
119. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006; 113: 544-554.
120. Wang L, Zhou Z, Saari JT, Kang YJ. Alcohol-induced myocardial fibrosis in metallothionein-null mice: Prevention by zinc supplementation. Am J Pathol 2005; 167: 337-344.
121. Wang P, Chen H, Qin H, et al. Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc Natl Acad Sci USA 1998; 95: 4556-4560.
122. 2+ cycling proteins, NADPH oxidase, poly(ADP-ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 2006; 40: 1419-1429.
123. Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett 2006; 394: 158-162.
124. Xiong Y, Liu X, Lee CP, et al. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med 2006; 41: 46-55.
125. Yang X, Doser TA, Fang CX, et al. Metallothionein prolongs survival and antagonizes senescence-associated cardiomyocyte diastolic dysfunction: Role of oxidative stress. FASEB J 2006; 20: 1024-1026.
126. Ye G, Metreveli NS, Donthi RV, et al. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 2004; 53: 1336-1343.
127. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003; 52: 777-783.
128. Yen HC, Oberley TD, Gairola CG, et al. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch Biochem Biophys 1999; 362: 59-66.
129. Yen HC, Oberley TD, Vichitbandha S, et al. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996; 98: 1253-1260.
130. Yin X, Wu H, Chen Y, Kang YJ. Induction of antioxidants by adriamycin in mouse heart. Biochem Pharmacol 1998; 56: 87-93.
131. Yoshida T, Watanabe M, Engelman DT, et al. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury. J Mol Cell Cardiol 1996; 28: 1759-1767.
132. Zhang X, Dong F, Li Q, et al. Cardiac overexpression of catalase antagonizes ADH- associated contractile depression and stress signaling after acute ethanol exposure in murine myocytes. JAppl Physiol 2005; 99: 2246-2254.
133. Zhang X, Klein AL, Alberle NS, et al. Cardiac-specific overexpression of catalase rescues ventricular myocytes from ethanol-induced cardiac contractile defect. J Mol Cell Cardiol 2003; 35: 645-652.
134. Zhou Z, Sun X, Kang YJ. Metallothionein protection against alcoholic liver injury through inhibition of oxidative stress. Exp Biol Med (Maywood) 2002; 227: 214-222.